The European Commission has approved Sanofi's MenQuadfi vaccine for use in infants as young as six weeks old to protect against invasive meningococcal disease caused by serogroups A, C, W, and Y. Previously approved for those aged 12 months and older, this extension allows earlier immunization aligned with routine infant vaccination schedules. The vaccine addresses a serious bacterial infection with high mortality and severe complications, especially in infants. This approval provides healthcare providers in the EU with a broader tool to protect vulnerable young children against this fast-progressing disease.
Sanofi has published its financial report for the first half of 2026, available on its website and filed with the French financial authority (AMF). The biopharmaceutical company highlights its innovation in R&D and use of AI to drive long-term growth...
Sanofi has published its half-year financial report for the period ending June 30, 2026, available on its website and filed with regulatory authorities in France and the US. The report highlights Sanofi's strong business performance, including double...
